Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Atlas Arteria ( (AU:ALX) ) has shared an announcement.
Atlas Arteria announced that the Supreme Court of Virginia upheld the State Corporation Commission’s decision to deny Toll Road Investors Partnership II’s toll rate application for the Dulles Greenway. This decision allows TRIP II’s federal case, which alleges constitutional violations, to proceed. TRIP II plans to submit a new rate application this year, indicating ongoing efforts to address toll rate issues.
The most recent analyst rating on (AU:ALX) stock is a Buy with a A$6.16 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
More about Atlas Arteria
Atlas Arteria is a company that partners to deliver world-class road experiences, focusing on creating long-term value through disciplined management and sustainable business practices. The group consists of toll road businesses in France, Germany, and the United States, including interests in the APRR, AREA, A79, and ADELAC motorway networks in France, the Chicago Skyway in the US, and the Warnow Tunnel in Germany.
Average Trading Volume: 2,146,891
Technical Sentiment Signal: Buy
Current Market Cap: A$7.3B
See more data about ALX stock on TipRanks’ Stock Analysis page.